In most people, the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) trigger mild cold-like symptoms. But in infants and seniors, these viruses can ...
Respiratory Syncytial Virus (RSV) is a leading cause of acute respiratory tract infection, with the greatest impact on infants, immunocompromised individuals, and older adults. RSV prevalence ...
Respiratory syncytial virus (RSV) can induce severe respiratory disease in infants and the elderly 1,2,3,4,5. RSV F, a class I fusion protein, facilitates the merging of viral and host cell membranes ...
Nirsevimab immunization at birth is associated with a lower risk for RSV-related LRTI hospitalization in infants compared with maternal vaccination.
For older adults, the vaccine against respiratory syncytial virus (RSV) appears to be most effective in the first year after administration, according to new research that shows the benefits of the ...
Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results